Wolfe Research upgraded MoonLake Immunotherapeutics (MLTX) to Outperform from Peer Perform with a $61 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLTX:
- MoonLake Immunotherapeutics: Buy Rating Driven by Strategic Developments and Promising Clinical Programs
- MoonLake Immunotherapeutics: Strong Financials and Promising Pipeline Drive Buy Rating
- MoonLake Immunotherapeutics: Strong Financial Position and Promising Data Releases Justify Buy Rating
- Promising Growth Potential and Financial Strength Drive Buy Rating for MoonLake Immunotherapeutics
- MoonLake Immunotherapeutics: Promising Clinical Developments and Market Opportunities Justify Buy Rating